Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3,024.00    46.00 (1.54%)
Bid:
3,031.00
Ask:
3,033.00
Spread: 2.00 (0.066%)
Market Cap: £4.21b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Completed divestment

1 Jul 2022 07:00

RNS Number : 9187Q
Croda International PLC
01 July 2022
 

Stock market announcement

1 July 2022

Completed divestment - transitioning to a pure-play Consumer Care and Life Sciences company

Croda International Plc ('Croda'), which uses smart science to create high performance ingredients and technologies that improve lives, today announces the completion of the divestment of the majority of its Performance Technologies and Industrial Chemicals businesses to a wholly owned subsidiary of Cargill Inc ('Cargill'), as more fully described in Croda's initial announcement on 22 December 2021.

The gross proceeds will be approximately €775m (approximately £667m), subject to small, customary adjustments for cash and debt-like instruments, and working capital, in line with the earlier announcement. The divestment and the associated proceeds exclude Croda Sipo ('Sipo'), a Chinese joint venture in which Croda has a 65% shareholding. Croda continues to discuss with its joint venture partner the acquisition of its stake in Sipo, to enable a subsequent sale by Croda to Cargill of 100% of Sipo for €140m. 

Steve Foots, Chief Executive of Croda, said: "This divestment accelerates Croda's transition to being a pure-play Consumer Care and Life Sciences company. We will redeploy capital and resources to scale our consumer, health and crop care technologies, helping to deliver consistent, superior sales growth and even stronger profit margins."

 

Further information

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Press: Charlie Armitstead, Teneo +44 7703 330269

 

Advisers to Croda

 

Morgan Stanley & Co. International Plc (Financial Adviser & Corporate Broker)

Shirav Patel, Andrew Foster

Centerview Partners (Financial Adviser)

James Hartop

Freshfields Bruckhaus Deringer (Legal Adviser)

Oliver Lazenby

Teneo (Financial PR)

Charlie Armitstead

 

Disclaimers

 

Morgan Stanley & Co. International plc ("Morgan Stanley") which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA in the UK is acting exclusively as financial adviser and corporate broker to Croda and no one else in connection with the matters set out in this announcement. In connection with such matters, Morgan Stanley, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

 

Centerview Partners UK LLP ("Centerview Partners") is authorised and regulated by the Financial Conduct Authority. Centerview Partners is acting exclusively for Croda and no one else in connection with the matters referred to in this announcement. Centerview Partners is not and will not be responsible to anyone other than Croda for providing the protections afforded to its clients or for providing advice in connection with the contents of this announcement or any other matter referred to in this announcement. Neither Centerview Partners, nor any of its affiliates, owes or accepts any duty, liability or responsibility whatsoever to any person who is not a client of Centerview Partners in connection with this announcement, any statement contained herein or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISFMMRTMTIJBIT
Date   Source Headline
4th Aug 20253:21 pmRNSDirector/PDMR Shareholding
4th Aug 202511:03 amRNSDirector/PDMR Shareholding
4th Aug 20258:46 amRNSDirector/PDMR Shareholding
1st Aug 20253:43 pmRNSDirector/PDMR Shareholding
1st Aug 20251:31 pmRNSDirector/PDMR Shareholding
31st Jul 20253:42 pmRNSDirector/PDMR Shareholding
29th Jul 20252:33 pmRNSDirector/PDMR Shareholding
29th Jul 20252:31 pmRNSDirector/PDMR Shareholding
29th Jul 20257:00 amRNSResults for the six months ended 30 June 2025
16th Jul 20252:08 pmRNSDirector/PDMR Shareholding
12th Jun 202510:01 amRNSDirector/PDMR Shareholding
6th Jun 20258:45 amRNSCorporate Broker Appointment
2nd Jun 20258:44 amRNSDirector/PDMR Shareholding
29th May 20258:57 amRNSDirector/PDMR Shareholding
13th May 20253:48 pmRNSDirector/PDMR Shareholding
6th May 20252:26 pmRNSDirector/PDMR Shareholding
24th Apr 202511:40 amRNSResult of AGM
23rd Apr 20257:00 amRNSFirst quarter 2025 sales update
11th Apr 20252:33 pmRNSDirector/PDMR Shareholding
11th Apr 20252:06 pmRNSDirector/PDMR Shareholding
7th Apr 202511:14 amRNSDirector/PDMR Shareholding
4th Apr 20253:49 pmRNSDirector/PDMR Shareholding
3rd Apr 20253:47 pmRNSDirector/PDMR Shareholding
31st Mar 202512:14 pmRNSDirector/PDMR Shareholding
27th Mar 20259:57 amRNSDirector Declaration
25th Mar 202512:30 pmRNSDirector/PDMR Shareholding
25th Mar 202512:27 pmRNSDirector/PDMR Shareholding
25th Mar 202512:26 pmRNSDirector/PDMR Shareholding
25th Mar 202512:23 pmRNSDirector/PDMR Shareholding
25th Mar 202512:21 pmRNSDirector/PDMR Shareholding
25th Mar 202512:21 pmRNSDirector/PDMR Shareholding
25th Mar 202512:17 pmRNSDirector/PDMR Shareholding
25th Mar 202512:14 pmRNSDirector/PDMR Shareholding
13th Mar 202512:38 pmRNSAnnual Financial Report
11th Mar 20252:54 pmRNSDirector/PDMR Shareholding
11th Mar 20257:13 amRNSDirector Declaration
10th Mar 202510:42 amRNSHolding(s) in Company
3rd Mar 20253:49 pmRNSDirectorate Change
25th Feb 202511:30 amRNSDirector/PDMR Shareholding
25th Feb 20257:00 amRNSFinal Results
11th Feb 20253:12 pmRNSDirector/PDMR Shareholding
13th Jan 20252:19 pmRNSDirector/PDMR Shareholding
11th Dec 20243:09 pmRNSDirector/PDMR Shareholding
11th Dec 20241:54 pmRNSDirector/PDMR Shareholding
9th Dec 20242:36 pmRNSHolding(s) in Company
29th Nov 202412:12 pmRNSHolding(s) in Company
20th Nov 20241:42 pmRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSDirectorate Change
12th Nov 20242:47 pmRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSThird quarter 2024 sales update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.